Monitor continued operational improvement and FDA updates on Hyalofast and Cingal. Maintained guidance and strong adjusted EBITDA suggest restructuring traction, but GAAP loss widening remains a concern. The stock may trade on adjusted profitability improvement rather than GAAP EPS miss.
ANIK drugs
ANIK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 29 $12.39entry
- T+1 · 7mo ago +0.48%α −0.54% · $12.45
- T+5 · 7mo ago +22.03%α +18.92% · $15.12
- T+20 · 6mo ago +20.26%α +14.21% · $14.90
- T+60 · 4mo ago +20.66%α +16.55% · $14.95
Price Chart
How similar events traded
Executive Summary
Anika Therapeutics reported Q1 2026 revenue of $29.6M, up 13% YoY and beating consensus of $28.1M, but GAAP EPS of -$0.37 missed the -$0.21 consensus by 76%, driven by $4.9M in one-time severance costs. Adjusted EBITDA surged to $4.3M from $0.1M and guidance was maintained, while two directors resigned effective at the annual meeting.
Key Financial Metrics
Key Facts
- Q1 revenue $29.6M, +13% YoY, beat consensus $28.1M
- GAAP diluted EPS from continuing ops -$0.37 vs consensus -$0.21 (miss)
- Adjusted diluted EPS $0.27 vs -$0.06 prior year
- Gross margin 64.2%, up 810 bps YoY from 56.1%
- Adjusted EBITDA $4.3M vs $0.1M prior year
- FY2026 guidance maintained: revenue $114-$122.5M
- $15M share repurchase completed at avg $10.76/share
- Two directors resign, board to shrink from 9 to 7 members
Financial Impact
Revenue beat of ~$1.5M (5.4%) vs consensus; EPS miss of $0.16 (-76%) vs consensus
Risk Factors
- GAAP loss per share widened to -$0.37 from -$0.28
- One-time severance costs of $4.9M obscuring underlying profitability
- FDA approval uncertainty for Hyalofast PMA and Cingal NDA
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-002799 |
| Document: f8k_042926.htm | 0001171843-26-002799 |
| Document: 0001171843-26-002799-index-headers.html | 0001171843-26-002799 |
| Document: 0001171843-26-002799-index.html | 0001171843-26-002799 |
| Document: 0001171843-26-002799.txt | 0001171843-26-002799 |
| 8-K Data (Synthetic) | 0001171843-26-002799 |
Track record
13 reports on ANIK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago 8-K Mixed 6/10 Entry $14.55 Now $12.92 −11.20% settles Feb 4
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $21.42 Now $12.92 −39.68% settles Jan 21
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $16.17 to $21.09 Now $12.92 −20.10% ▲ +30.43% +25.70% vs SPY
- Jul 14, 202617w ago 8-K Neutral 3/10 Entry $15.93 to $19.23 Now $12.92 −18.90% ▲ +20.72% +18.18% vs SPY
- Jun 23, 202620w ago 8-K Neutral 4/10 Entry $14.73 to $21.03 Now $12.92 −12.29% ▲ +42.77% +39.93% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $14.72 to $21.04 Now $12.92 +12.23% ▼ −42.93% −39.67% vs SPY
- Jun 8, 202623w ago DEFA14A Neutral 4/10 Entry $14.60 to $21.11 Now $12.92 −11.51% ▲ +44.59% +41.54% vs SPY
- Jun 1, 202624w ago DEFA14A Neutral 3/10 Entry $14.63 to $21.40 Now $12.92 −11.69% ▲ +46.27% +45.04% vs SPY
- Apr 30, 202628w ago Insider Cluster Mixed 5/10 Entry $14.85 to $16.17 Now $12.92 −13.00% ▲ +8.89% +7.41% vs SPY
- Apr 29, 202628w ago 8-K Mixed 6/10 Viewing Entry $12.39 to $14.95 Now $12.92 +4.28% ▲ +20.66% +16.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers